Abstract:Photoresponsive ruthenium (Ru) complexes have been extensively studied in the photodynamic therapy (PDT) of cancer. The metal-to-ligand charge transfer (MLCT) absorption maximum of most Ru complexes is located in the short-wavelength visible region, which is well suited for superficial tumors but shows inefficient therapeutic effects for more deep-seated ones. Moreover, Ru complexes are primarily located in the mitochondria or nucleus, always resulting in high levels of dark toxicity and DNA mutation. Herein, we reported a new ruthenium complex (Ru-I) for red-light-triggered PDT. The activation wavelength of Ru-I is successfully extended to 660 nm. Importantly, the complex photosensitizer can be quickly taken up by cancer cells and selectively accumulated in the lysosome, an ideal localization for PDT purposes. Intratumoral injection of Ru-I into tumor-bearing mice achieved excellent therapeutic effects and thus holds great promise for applications in lysosome localization photodynamic therapy.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acsami.0c22551?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acsami.0c22551</a>.Experimental details including synthetic methods of Ru-I and characterization; ESI-HRMS spectrum of compound 3 (Figure S1); 1H NMR spectrum of compound 3 (Figure S2); ESI-HRMS spectrum of compound 4 (Figure S3); 1H NMR and 13C NMR spectra of compound 4 (Figure S4); purity of Ru-I measurement by HPLC (Figure S5); HOMO and LUMO orbitals for Ru-I (Figure S6); absorption and emission spectrum of Ru-I in different solvents (Figure S7); stability of Ru-I with different treatments (Figures S8 and S9); ROS generation analysis (Figures S10–S12); cell imaging experiments (Figures S13–S17); in vitro photocytotoxicity evaluation (Figures S18–S20); and animal experiments (Figures S21 and S22) (<a class="ext-link" href="/doi/suppl/10.1021/acsami.0c22551/suppl_file/am0c22551_si_001.pdf">PDF</a>)This article has not yet been cited by other publications.

Diatom-like silica–protein nanocomposites for sustained drug delivery of ruthenium polypyridyl complexes

Polydiacetylene/lipid-coated red-emissive silica nanorods for the sustained release and ameliorated anticancer efficacy of a Ru(arene) complex bearing piperlongumine natural product

Protein Nanocages for Delivery and Release of Luminescent Ruthenium(II) Polypyridyl Complexes.

pH-Responsive Release of Ruthenium Metallotherapeutics from Mesoporous Silica-Based Nanocarriers

Synthesis of Novel Core–shell Structural AuNR@MCM-41 for Infrared Light-Driven Release of Drug

Fortuitous synthesis of unsaturated half-sandwich Ruthenium(II) complexes via solvent-involved rearrangement and their biological evaluation

Polymeric micelle-mediated delivery of half-sandwich ruthenium(II) complexes with phosphanes derived from fluoroloquinolones for lung adenocarcinoma treatment

A lysosome-targeted ruthenium(II) polypyridyl complex as photodynamic anticancer agent

Red-Light-Responsive Ru Complex Photosensitizer for Lysosome Localization Photodynamic Therapy

Biodegradable Ruthenium‐Rhenium Complexes Containing Nanoamplifiers: Triggering ROS‐Induced CO Release for Synergistic Cancer Treatment

Ruthenium-loaded mesoporous silica as tumor microenvironment-response nano-fenton reactors for precise cancer therapy

A RuII Polypyridyl Alkyne Complex Based Metal-Organic Frameworks for Combined Photodynamic/Photothermal/Chemotherapy.

Sonoinduced Tumor Therapy and Metastasis Inhibition by a Ruthenium Complex with Dual Action: Superoxide Anion Sensitization and Ligand Fracture

pH‐Responsive, Self‐Assembled Ruthenium Nanodrug: Dual Impact on Lysosomes and DNA for Synergistic Chemotherapy and Immunogenic Cell Death

New Nanostructured Materials Based on Mesoporous Silica Loaded with Ru(II)/Ru(III) Complexes with Anticancer and Antimicrobial Properties

Electrochemical and Electrochemiluminescence Study of Ru(bpy)(2+)3-doped Silica Nanoparticles with Covalently Grafted Biomacromolecules.

A Bimetallic Nanozyme with Cascade Effect for Synergistic Therapy of Cancer

Photoinduced synergistic cytotoxicity towards cancer cells <i>via</i> Ru(II) complexes

Two Ru(II) compounds with aggregation induced emission as promising photosensitizers for photodynamic therapy

Ru(ii) polypyridyl complex-incorporated and folate-conjugated vehicle for cancer cell imaging and photoinduced inactivation.

Improving ruthenium nanoparticle physicochemical properties and chemotherapeutic efficacy by dual-encapsulating with new amphiphilic chitosan and imidazolium ionic liquid